GlaxoSmithKline
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, GlaxoSmithKline sits in the top decile of US sponsors by registered trial count (#17 of 15,742 sponsors by registered trial count).
GlaxoSmithKline: 1,345 sponsored US clinical trials, 50 recruiting.
GlaxoSmithKline sponsors 1,345 registered US clinical trials on ClinicalTrials.gov, 50 of them currently recruiting, and 1,130 completed. 486 of these trials are in Phase 3-4 (later-stage) and 791 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pulmonary Disease, Chronic Obstructive, with 30 trials.
Top-decile sponsor footprint
GlaxoSmithKline ranks in the top decile of sponsors by registered trial count (#17 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,130 of 1,249 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,345 total, page 24 of 27
fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With Social Anxiety Disorder
NCT00332046
Effects Of GW679769 On Sleep Onset And Maintenance,And Next Day Functioning In The Elderly And Non-elderly With Primary Insomnia
NCT00280436
Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients
NCT00332319
Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subjects With Hepatic Impairment
NCT00359177
Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy
NCT00235755
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NCT00321477
Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints
NCT00292552
Effect Of GW501516X On How The Heart Obtains And Uses Energy
NCT00318617
To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients
NCT00258050
Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects
NCT00903409
Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)
NCT00256854
Observational Study Of An Electronic Questionnaire In Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00259909
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
NCT00244751
Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus
NCT00259987
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
NCT00240643
SB-480848 In Subjects With Coronary Heart Disease
NCT00269048
Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer
NCT00320385
Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks
NCT00240617
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
NCT00244764
Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer
NCT00267488
Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks
NCT00240630
Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome
NCT00355641
Study Comparing the Immune Response of Fluarix and Fluzone Influenza Vaccines
NCT00197288
Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa
NCT00264615
Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy
NCT00232596
Study Of Patients With Allergic Rhinitis And Asthma
NCT00296530
Study Of Allergic Rhinitis In Patients Who Also Have Asthma
NCT00296491
SB-773812 Administered In Adults With Schizophrenia
NCT00259870
Odiparcil For The Prevention Of Venous Thromboembolism
NCT00244725
Study In People With Type 2 Diabetes
NCT00196989
A Study In Patients With Type 2 Diabetes Mellitus
NCT00256867
Cyclophosphamide Drug Interaction Study In Cancer Patients
NCT00334646
Once-Daily Investigational Nasal Spray In Adults And Adolescents With Seasonal Allergic Rhinitis (SAR)
NCT00197262
A Study To Assess The Quality Of Bone In Patients Taking Oral Ibandronate Versus Placebo
NCT02948881
A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder
NCT00273039
Study Of Adults And Adolescents With Vasomotor Rhinitis
NCT00117325
Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor Rhinitis
NCT00118703
Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV
NCT00244712
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
NCT00123903
Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects
NCT00197197
Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeable Virus
NCT00321438
Ropinirole Tablets In Young Patients With Restless Legs Syndrome
NCT00140712
First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin
NCT00316186
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
NCT00113308
Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome
NCT00197080
Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140
NCT00123890
A New Oral Treatment For Type II Diabetes Mellitus
NCT00111800
Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer
NCT00111787
SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C
NCT00110799
Study In Adolescent And Adult Subjects 12 Years Of Age And Older With Seasonal Allergic Rhinitis To Assess Onset of Action
NCT00118729
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 440 |
| Phase 2 | 351 |
| Phase 3 | 377 |
| Phase 4 | 109 |
Therapeutic Areas
What is open in the GlaxoSmithKline pipeline
50 recruiting of 1,345 indexed (4% open); 1,130 completed (84%).
Phase mix: 486 late (III/IV) vs 791 early (I/II) (early-phase heavy).
Top condition: Pulmonary Disease, Chronic Obstructive (30 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
GlaxoSmithKline: open-pipeline peers nationwide
Peers matched on 1,345 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
GlaxoSmithKline sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,345 trials (± recruiting share)
- Eli Lilly and Company · 1,341 trials · 9% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
- AstraZeneca · 1,285 trials · 12% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Stryker Orthopaedics · 4% recruiting · 27 trials
- US Oncology Research · 4% recruiting · 27 trials
- Otsuka Pharmaceutical Development & Commercialization · 4% recruiting · 221 trials
- Teva Branded Pharmaceutical Products R&D · 4% recruiting · 167 trials
Related
What to do with this GlaxoSmithKline page
1,345 registered trials is a research-attention snapshot, not an endorsement of GlaxoSmithKline or any single study.
- 50 of GlaxoSmithKline's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Pulmonary Disease, Chronic Obstructive is the condition GlaxoSmithKline studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pulmonary Disease, Chronic Obstructive trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. GlaxoSmithKline pipeline card: 1,345 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.